Cargando…

Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China

The National Free Antiretroviral Treatment Program was implemented in Jiangsu Province, China in 2005. We conducted a retrospective, open cohort study to determine treatment failure rates and associated risk factors. Data were obtained from the national web-based antiretroviral treatment database. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Tao, Ding, Ping, Fu, Gengfeng, Huan, Xiping, Xu, Xiaoqin, Zhang, Zhi, Liu, Xiaoyan, Yang, Haitao, Mandel, Jeff, Wei, Chongyi, McFarland, Willi, Yan, Hongjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318988/
https://www.ncbi.nlm.nih.gov/pubmed/28220792
http://dx.doi.org/10.1038/srep42381
_version_ 1782509292775014400
author Qiu, Tao
Ding, Ping
Fu, Gengfeng
Huan, Xiping
Xu, Xiaoqin
Zhang, Zhi
Liu, Xiaoyan
Yang, Haitao
Mandel, Jeff
Wei, Chongyi
McFarland, Willi
Yan, Hongjing
author_facet Qiu, Tao
Ding, Ping
Fu, Gengfeng
Huan, Xiping
Xu, Xiaoqin
Zhang, Zhi
Liu, Xiaoyan
Yang, Haitao
Mandel, Jeff
Wei, Chongyi
McFarland, Willi
Yan, Hongjing
author_sort Qiu, Tao
collection PubMed
description The National Free Antiretroviral Treatment Program was implemented in Jiangsu Province, China in 2005. We conducted a retrospective, open cohort study to determine treatment failure rates and associated risk factors. Data were obtained from the national web-based antiretroviral treatment database. WHO criteria were used to define immunologic treatment failure. Kaplan-Meier methods were used to determine treatment failure rates and Cox proportional hazards modeling was used to identify risk factors. A total of 5,083 (87.8%) having at least one CD4 cell count measure were included from 2005 to 2013. Overall, 30.4% had immunologic treatment failure with cumulative treatment failure rates increasing to 50.5% at month 60 and 64.1% at month 90. Factors predicting treatment failure included being treated in the Centers for Disease Control and Prevention system (HR 1.69, 95% CI 1.14–2.50, p = 0.009) or jail hospital (HR 1.20, 95% CI 1.08–1.34, p = 0.001), and having a baseline CD4 count >350 cells/uL (HR 2.37, 95% CI 1.94–2.89. p < 0.001). Immunologic treatment failure was moderate to substantial among treated HIV patients. Providing second-line regimens and shifting treatment providers to professional hospitals should be considered to consolidate gains in averting morbidity and mortality.
format Online
Article
Text
id pubmed-5318988
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53189882017-02-24 Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China Qiu, Tao Ding, Ping Fu, Gengfeng Huan, Xiping Xu, Xiaoqin Zhang, Zhi Liu, Xiaoyan Yang, Haitao Mandel, Jeff Wei, Chongyi McFarland, Willi Yan, Hongjing Sci Rep Article The National Free Antiretroviral Treatment Program was implemented in Jiangsu Province, China in 2005. We conducted a retrospective, open cohort study to determine treatment failure rates and associated risk factors. Data were obtained from the national web-based antiretroviral treatment database. WHO criteria were used to define immunologic treatment failure. Kaplan-Meier methods were used to determine treatment failure rates and Cox proportional hazards modeling was used to identify risk factors. A total of 5,083 (87.8%) having at least one CD4 cell count measure were included from 2005 to 2013. Overall, 30.4% had immunologic treatment failure with cumulative treatment failure rates increasing to 50.5% at month 60 and 64.1% at month 90. Factors predicting treatment failure included being treated in the Centers for Disease Control and Prevention system (HR 1.69, 95% CI 1.14–2.50, p = 0.009) or jail hospital (HR 1.20, 95% CI 1.08–1.34, p = 0.001), and having a baseline CD4 count >350 cells/uL (HR 2.37, 95% CI 1.94–2.89. p < 0.001). Immunologic treatment failure was moderate to substantial among treated HIV patients. Providing second-line regimens and shifting treatment providers to professional hospitals should be considered to consolidate gains in averting morbidity and mortality. Nature Publishing Group 2017-02-21 /pmc/articles/PMC5318988/ /pubmed/28220792 http://dx.doi.org/10.1038/srep42381 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Qiu, Tao
Ding, Ping
Fu, Gengfeng
Huan, Xiping
Xu, Xiaoqin
Zhang, Zhi
Liu, Xiaoyan
Yang, Haitao
Mandel, Jeff
Wei, Chongyi
McFarland, Willi
Yan, Hongjing
Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China
title Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China
title_full Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China
title_fullStr Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China
title_full_unstemmed Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China
title_short Immunologic treatment failure among HIV-infected adult patients in Jiangsu province, China
title_sort immunologic treatment failure among hiv-infected adult patients in jiangsu province, china
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318988/
https://www.ncbi.nlm.nih.gov/pubmed/28220792
http://dx.doi.org/10.1038/srep42381
work_keys_str_mv AT qiutao immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina
AT dingping immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina
AT fugengfeng immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina
AT huanxiping immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina
AT xuxiaoqin immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina
AT zhangzhi immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina
AT liuxiaoyan immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina
AT yanghaitao immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina
AT mandeljeff immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina
AT weichongyi immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina
AT mcfarlandwilli immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina
AT yanhongjing immunologictreatmentfailureamonghivinfectedadultpatientsinjiangsuprovincechina